Regeneron, Bayer’s Eye Drug Fulfills its Primary Goal

Regeneron, Bayer’s Eye Drug Fulfills its Primary GoalRegeneron Pharmaceuticals and Bayer HealthCare, a U. S. unit of Germany's Bayer, announced Thursday their experimental drug VEGF Trap-Eye, to treat retinal swelling brought on by diabetes, fulfilled its primary aim in a mid-stage study.

The drug VEGF Trap-Eye is being experimented for the condition known as diabetic macular edema -- the most prevalent cause of moderate vision loss in patients with diabetes. It is a disease of the retina that engulfs individuals with diabetes and can result in blindness.

The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.

The study revealed that the patients receiving the drug fetched a significant improvement in visual acuity over 24 weeks compared to patients receiving the standard care, macular laser therapy.

The companies also said the drug was generally well tolerated, with no serious adverse events reported.

Shares of Regeneron, Tarrytown based company, closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.